Advertisement CircuLite names new CFO - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

CircuLite names new CFO

CircuLite, a developer of minimally-invasive devices for long-term partial circulatory support, has appointed Peter Pfreundschuh as its new CFO.

Most recently, Mr Pfreundschuh was executive director of business development and licensing at AstraZeneca, where he led finance and negotiations in support of new business development opportunities for all external deals and alliances.

Mr Pfreundschuh holds an MBA with a concentration in finance from Rider University and BS in accounting from Rutgers University School of Business.

Paul Southworth, president and CEO of CircuLite, said: “Peter brings to CircuLite extensive experience with operational finance, business development, executing licensing deals, and strategic planning.

“His expertise will be a valuable asset to the company, as we continue our European registration trial for the long-term use of our Synergy micro-pump, pursue CE Mark certification in 2009, and plan to initiate a pilot trial under an investigational device exemption in the US.”